Transthera Biosciences Co. Ltd. has described NLRP3 inflammasome inhibitors reported to be useful for the treatment of autoimmune disease, inflammatory disorders and immunological disorders.

Genep Inc. has divulged sodium channel protein type 8 subunit α (SCN8A; Nav1.6) blockers reported to be useful for the treatment of epilepsy.

Novo Nordisk A/S has identified C-type natriuretic peptide (CNP) compounds reported to be useful for the treatment of achondroplasia and heart failure.

Scientists at Shanghai Synergy Pharmaceutical Sciences Co. Ltd. and Zhejiang Huahai Pharmaceutical Group Co. Ltd. have synthesized non-receptor tyrosine-protein kinase TYK2 inhibitors reported to be useful for the treatment of psoriasis, inflammatory bowel disease (IBD) and lupus erythematosus.

Scientists at Hansoh Bio LLC, Hansoh Pharmaceutical Group Co. Ltd. and Shanghai Hansoh Biomedical Co. Ltd. have disclosed antibody-drug conjugates (ADCs) comprising HER3 (erbB3)-targeting antibodies linked to a cytotoxic drug through a linker.

Merck Sharp & Dohme LLC has described antibody-drug conjugates (ADCs) comprising antibodies targeting tumor-associated calcium signal transducer 2 (TACSTD2; TROP2) linked to exatecan through a linker reported to be useful for the treatment of cancer.

Hangzhou Synrx Therapeutics Technology Co. Ltd. has divulged DNA polymerase θ (POLθ, POLQ) inhibitors reported to be useful for the treatment of cancer.

Boehringer Ingelheim Pharma GmbH & Co. KG has identified stimulator of interferon genes protein (STING; TMEM173) agonists reported to be useful for the treatment of cancer, allergy, autoimmune disease, inflammatory disorders and infections.

Shanghai Yidi Biotechnology Co. Ltd. has synthesized peptide-based nitrile compounds acting as dipeptidyl peptidase 1 (DPP-1, cathepsin C) inhibitors reported to be useful for the treatment of cancer, infections, and respiratory, metabolic, cardiovascular, cerebrovascular and autoimmune diseases.

Suzhou Genhouse Bio Co. Ltd. has disclosed transcriptional coactivator YAP1/transcriptional enhancer factor (TEAD) interaction inhibitors reported to be useful for the treatment of fibrosis, skin lesions, tissue repair and regeneration and cancer.